Targeted Therapies for Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units
"Clinicians targeted the viral infection with a variety of specific therapies in 28 patients (61%). The most common of these was hydroxychloroquine, either as a single agent or in combination. Azithromycin was used in 8 children as a single agent in 1 patient and in combination with hydroxychloroquine in the remaining 7 patients. Remdisivir was used in 8 patients, including as a single agent in 2 and in combination in 6. Tocilizumab was used in 5 children, including as a single agent in 1 patient, in combination with hydroxychloroquine in 1, in combination with hydroxychloroquine and azithromycin in 1, in combination with hydroxychloroquine and remdisivir in 1, and in combination with convalescent plasma in 1."
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Patient Characteristics and Clinical Trajectories for Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units
Targeted Therapies for Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units
Outcomes for Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units
Table 1. Presentation and Demographic Characteristics of 48 Children Treated in Pediatric Intensive Care Units for Coronavirus Disease 2019 (COVID-19)